Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro

Nanotechnology

Volumn 23, Issue 49, 2012, Pages

  Wang, Ying ^a   Guo, Miao ^a   Lu, Yu ^a   Ding, Li Ying ^a   Ron, Wen Ting ^a   Liu, Ya Qing ^a   Song, Fei Fei ^a   Yu, Shu Qin ^a  

^a NANJING NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER CHEMOTHERAPY; ANTICANCER DRUG; ANTICANCER EFFECTS; ATP-BINDING SITE; CAMPTOTHECIN (CPT); CONTROLLED RELEASE; DELIVERY SYSTEMS; EFFLUX PUMPS; IN-VITRO; INTRACELLULAR ACCUMULATION; MICROENVIRONMENTS; MODEL DRUGS; MULTIDRUG RESISTANCE; NARROW SIZE DISTRIBUTIONS; P-GLYCOPROTEIN; PHYSICO-CHEMICAL CHARACTERIZATION; POLY LACTIC-CO-GLYCOLIC ACID; SMOOTH SURFACE; SPHERICAL PARTICLE; THERAPEUTIC EFFECTS; TIME-DEPENDENT;

CELLS; CHEMOTHERAPY; CYTOLOGY; DRUG DELIVERY; EMULSIFICATION; ENZYME ACTIVITY; MODULATORS; MOLECULAR BIOLOGY; NANOPARTICLES; POLYETHYLENE GLYCOLS;

COPOLYMERS;

ALPHA TOCOPHEROL; ALPHA TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; LACTIC ACID; MACROGOL DERIVATIVE; NANOCAPSULE; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; CHEMISTRY; DRUG RESISTANCE; EMULSION; EXPERIMENTAL NEOPLASM; HUMAN; MATERIALS TESTING; MULTIDRUG RESISTANCE; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EMULSIONS; HUMANS; LACTIC ACID; MATERIALS TESTING; NANOCAPSULES; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; VITAMIN E;

EID: 84869988607     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/23/49/495103     Document Type: Article

References (55)

1. Siew A, Le H, Thiovolet M, Gellert P, Schatzlein A and Uchegbu I 2012 Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharmacol. 9 14-28
2. Krishna R and Mayer L D 2000 Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur. J. Pharm. Sci. 11 265-83
3. O'Driscoll L and Clynes M 2006 Molecular markers of multiple drug resistance in breast cancer Chemotherapy 52 125-9
4. Krishna R and Mayer L D 2001 Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators Curr. Med. Chem. Anticancer Agents 1 163-74
5. Lin J H and Yamazaki M 2003 Role of P-glycoprotein in pharmacokinetics: clinical implications Clin. Pharmacokinet 42 59-98
6. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo A T and Bates S E 2012 Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies Drug Resist. Updat 15 50-61
7. Song Z, Feng R, Sun M, Guo C, Gao Y, Li L and Zhai G 2011 Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo J. Colloid Interface Sci. 354 116-23
8. Wang H, Zhao P, Su W, Wang S, Liao Z, Niu R and Chang J 2010 PLGA/polymeric liposome for targeted drug and gene co-delivery Biomaterials 31 8741-8
9. Narayanan S, Binulal N S, Mony U, Manzoor K, Nair S and Menon D 2010 Folate targeted polymeric 'green' nanotherapy for cancer Nanotechnology 21 285107
10. Roger E, Lagarce F, Garcion E and Benoit J P 2009 Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis J. Control. Release 140 174-81
11. Song X R et al 2010 Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma J. Pharm. Sci. 99 4874-9
12. Song X R, Cai Z, Zheng Y, He G, Cui F Y, Gong D Q, Hou S X, Xiong S J, Lei X J and Wei Y Q 2009 Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles Eur. J. Pharmaceut. Sci. 37 300-5
13. Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X and Lee R J 2007 Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil J. Pharm. Pharm. Sci. 10 350-7
14. Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H and Sugiyama Y 2007 Effect of excipients on breast cancer resistance protein substrate uptake activity J. Control. Release 124 1-5
15. Dinarvand R, Sepehri N, Manoochehri S, Rouhani H and Atyabi F 2011 Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents Int. J. Nanomed. 6 877-95
16. Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, Wang H, Zhou Q and Yu S 2011 PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms J. Agric. Food Chem. 59 9280-9
17. Zhang Z, Tan S and Feng S S 2012 Vitamin E TPGS as a molecular biomaterial for drug delivery Biomaterials 33 4889-906
18. Feng S S, Mei L, Anitha P, Gan C W and Zhou W 2009 Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel Biomaterials 30 3297-306
19. Dintaman J M and Silverman J A 1999 Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) Pharmacol. Res. 16 1550-6
20. Mu L and Feng S S 2002 Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol) J. Control. Release 80 129-44
21. Lee S H, Zhang Z and Feng S S 2007 Nanoparticles of poly(lactide)- tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery Biomaterials 28 2041-50
22. Zhang Z, Lee S H, Gan C W and Feng S S 2008 In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy Pharmacol. Res. 25 1925-35
23. Mu L and Feng S S 2003 PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio Pharmacol. Res. 20 1864-72
24. Zhao L and Feng S S 2010 Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies J. Pharm. Sci. 99 3552-60
25. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K 1991 Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 4187-91
26. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y and Saijo N 1995 A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38 Japan. J. Cancer Res. 86 101-10
27. Yang X, Hu Z, Chan S Y, Goh B C, Duan W, Chan E and Zhou S 2005 Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat J. Chromatogr. B 821 221-8
28. Gu Q, Xing J Z, Huang M, He C and Chen J 2012 SN-38 loaded polymeric micelles to enhance cancer therapy Nanotechnology 23 205101
29. Lei S, Chien P Y, Sheikh S, Zhang A, Ali S and Ahmad I 2004 Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice Anticancer Drugs 15 773-8
30. Kolhatkar R B, Swaan P and Ghandehari H 2008 Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers Pharmacol. Res. 25 1723-9
31. Chu X Y et al 1998 Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters Cancer Res. 58 5137-43
32. Xuan T, Zhang J A and Ahmad I 2006 HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38 J. Pharm. Biomed. Anal. 41 582-8
33. Chen Z S, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K and Akiyama S I 1999 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P Mol. Pharmacol. 55 921-8
34. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson J W, Kaakaji R, Morimura T, Kikuchi H, Takeuchi J and Barnett G H 1997 Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11 Cancer Chemother. Pharmacol. 39 417-23
35. Chen C, Xie X X, Zhou Q, Zhang F Y, Wang Q L, Liu Y Q, Zou Y, Tao Q, Ji X M and Yu S Q 2012 EGF-functionalized single-walled carbon nanotubes for targeting delivery of etoposide Nanotechnology 23 045104
36. Papadopulos F, Spinelli M, Valente S, Foroni L, Orrico C, Alviano F and Pasquinelli G 2007 Common tasks in microscopic and ultrastructural image analysis using ImageJ Ultrastruct. Pathol. 31 401-7
37. Wischke C, Zhang Y, Mittal S and Schwendeman S P 2010 Development of PLGA-based injectable delivery systems for hydrophobic fenretinide Pharmacol. Res. 27 2063-74
38. Takahashi A, Ohkohchi N, Yasunaga M, Kuroda J, Koga Y, Kenmotsu H, Kinoshita T and Matsumura Y 2010 Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases Clin. Cancer Res. 16 4822-31
39. Xia H, Gao X, Gu G, Liu Z, Zeng N, Hu Q, Song Q, Yao L, Pang Z, Jiang X, Chen J and Chen H 2011 Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration Biomaterials 32 9888-98
40. Kawase M, Sakagami H, Motohashi N, Hauer H, Chatterjee S S, Spengler G, Vigyikanne A V, Molnar A and Molnar J 2005 Coumarin derivatives with tumor-specific cytotoxicity and multidrug resistance reversal activity In Vivo 19 705-11
41. Zastre J A, Jackson J K, Wong W and Burt H M 2008 P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity Mol. Pharmaceut. 5 643-53
42. Zastre J, Jackson J, Bajwa M, Liggins R, Iqbal F and Burt H 2002 Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by Caco-2 cells using low molecular weight methoxypolyethylene glycol-block- polycaprolactone diblock copolymers Eur. J. Pharm. Biopharm. 54 299-309
43. Huang Z, Tong Y, Wang J and Huang Y 2003 NMR studies of the relationship between the changes of membrane lipids and the cisplatin-resistance of A549/DDP cells Cancer Cell Int. 3 5
44. Liang X and Huang Y 2002 Physical state changes of membrane lipids in human lung adenocarcinoma A(549) cells and their resistance to cisplatin Int. J. Biochem. Cell Biol. 34 1248-55
45. Liang X and Huang Y 2001 Alteration of membrane lipid biophysical properties and resistance of human lung adenocarcinoma A(549) cells to cisplatin Sci. China C 44 25-32
46. Salomon J J and Ehrhardt C 2011 Nanoparticles attenuate P-glycoprotein/MDR1 function in A549 human alveolar epithelial cells Eur. J. Pharm. Biopharm. 77 392-7
47. Zhao S, Dai W, He B, Wang J, He Z, Zhang X and Zhang Q 2012 Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms J. Control. Release 158 413-23
48. Varma M V, Ashokraj Y, Dey C S and Panchagnula R 2003 P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement Pharmacol. Res. 48 347-59
49. Constantinides P P and Wasan K M 2007 Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies J. Pharm. Sci. 96 235-48
50. Sun J, He Z G, Cheng G, Wang S J, Hao X H and Zou M J 2004 Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction Med. Sci. Monit. 10 RA5-14
51. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R and Coffin M 1999 Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability Pharmacol. Res. 16 1812-7
52. Collnot E M, Baldes C, Schaefer U F, Edgar K J, Wempe M F and Lehr C M 2010 Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access Mol. Pharmacol. 7 642-51
53. Collnot E M, Baldes C, Wempe M F, Kappl R, Huttermann J, Hyatt J A, Edgar K J, Schaefer U F and Lehr C M 2007 Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity Mol. Pharmacol. 4 465-74
54. Sahay G, Alakhova D Y and Kabanov A V 2010 Endocytosis of nanomedicines J. Control. Release 145 182-95
55. Derakhshandeh K, Hosseinalizadeh A and Nikmohammadi M 2011 The effects of PLGA microparticles on intestinal absorption of P-glycoprotein substrate using the everted rat intestinal sac model Arch. Pharmacol. Res. 34 1989-97